The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2017 | PD-L1 testing in first-line treatment of NSCLC
In this interview, Benjamin Besse, MD, PhD, Institut Gustave Roussy, Paris, France, addresses challenges associated with PD-L1 testing, and advocates for reflex PD-L1 testing at the time of diagnosis of non-small cell lung cancer (NSCLC). Reflex testing for EGFR mutations, ALK rearrangements and PD-L1 would help treating oncologists to optimise treatment decisions and avoid delays in treatment.
Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
